EIDD-2801 is an isopropylester prodrug of the ribonucleoside analog N 4-hydroxycytidine (EIDD-1931) that has shown broad influenza virus and multiple coronaviruses activity.

EIDD-2801 was orally bioavailable in ferrets and nonhuman primates.?Therapeutic oral dosing of influenza virus-infected ferrets reduced group pandemic 1 and group 2 seasonal influenza A shed virus load by multiple orders of magnitude and alleviated fever, airway epithelium histopathology, and inflammation, whereas postexposure prophylactic dosing was sterilizing[1].

2349386-89-4

C13H19N3O7

329.309

Molnupiravir;EIDD-2801

[1]Mart Toots , Jeong-Joong Yoon , Michael Hart ,et al.Quantitative Efficacy Paradigms of the Influenza Clinical Drug Candidate EIDD-2801 in the Ferret Model.ransl Res. 2020 Apr;218:16-28. [2]Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866. [3]Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883.

[1]Li Y, Liu M, Yan Y, et al. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo. Viruses. 2022, 14(6): 1142

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years